miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation

Oncotarget

Volumn 6, Issue 2, 2015, Pages 1276-1285

  Zou, Zhi Jian ^a,b   Fan, Lei ^a   Wang, Li ^a   Xu, Ji ^a   Zhang, Run ^a   Tian, Tian ^a   Li, Jian Yong ^a   Xu, Wei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chronic lymphocytic leukemia; MicroRNA; Mutation; PTEN

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA 214; MICRORNA 26A; MICRORNA INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MICRORNA; MIRN214 MICRORNA, HUMAN; MIRN26A MICRORNA, HUMAN; PTEN PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EXON; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; PROMOTER REGION; PROTEIN RNA BINDING; PTEN GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA GENE; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; 3' UNTRANSLATED REGION; DNA SEQUENCE; GENETICS; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL CULTURE;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; BLOTTING, WESTERN; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICRORNAS; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84921779149     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2626     Document Type: Article

References (44)

1. Diehl LF, Karnell LH and Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer. 1999; 86(12):2684-2692.
2. Ahn YO, Koo HH, Park BJ, Yoo KY and Lee MS. Incidence estimation of leukemia among Koreans. Journal of Korean medical science. 1991; 6(4):299-307.
3. Tamura K, Sawada H, Izumi Y, Fukuda T, Utsunomiya A, Ikeda S, Uike N, Tsukada J, Kawano F, Shibuya T, Gondo H, Okamura S, Suzumiya J and Kyushu Hematology Organization for Treatment Study G. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. European journal of haematology. 2001; 67(3):152-157.
4. Wu SJ1, Huang SY, Lin CT, Lin YJ, Chang CJ, Tien HF. The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect. Blood. 2010;116(22):4430-4435.
5. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC and Johnson AJ. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010; 116(12):2078-2088.
6. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2012; 2012:88-96.
7. Jin G, Kim MJ, Jeon HS, Choi JE, Kim DS, Lee EB, Cha SI, Yoon GS, Kim CH, Jung TH and Park JY. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer. 2010; 69(3):279-283.
8. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF and Ellis IO. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. The Journal of pathology. 2004; 204(1):93-100.
9. Mizoguchi M, Nutt CL, Mohapatra G and Louis DN. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain pathology. 2004; 14(4):372-377.
10. Oda K, Stokoe D, Taketani Y and McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer research. 2005; 65(23):10669-10673.
11. Ollikainen M, Gylling A, Puputti M, Nupponen NN, Abdel-Rahman WM, Butzow R and Peltomaki P. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. International journal of cancer Journal international du cancer. 2007; 121(4):915-920.
12. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff SA and Downing JR. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446(7137):758-764.
13. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, Bhagat G, Agarwal AM, Basso G, Castillo M, Nagase S, Cordon-Cardo C, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature medicine. 2007; 13(10):1203-1210.
14. Zou ZJ, Zhang R, Fan L, Wang L, Fang C, Zhang LN, Yang S, Li YY, Li JY and Xu W. Low expression level of phosphatase and tensin homolog deleted on chromosome ten predicts poor prognosis in chronic lymphocytic leukemia. Leukemia & lymphoma. 2013; 54(6):1159-1164.
15. Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang YH, Liu P, Hong M, Miao KR, Xu W and Li JY. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis. 2012; 33(7):1294-1301.
16. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ and Burger JA. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011; 118(13):3603-3612.
17. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA: the journal of the American Medical Association. 2011; 305(1):59-67.
18. Gronbaek K, Zeuthen J, Guldberg P, Ralfkiaer E and Hou-Jensen K. Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood. 1998; 91(11):4388-4390.
19. Nakahara Y, Nagai H, Kinoshita T, Uchida T, Hatano S, Murate T and Saito H. Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 1998; 12(8):1277-1280.
20. Chang H, Qi XY, Claudio J, Zhuang L, Patterson B and Stewart AK. Analysis of PTEN deletions and mutations in multiple myeloma. Leukemia research. 2006; 30(3):262-265.
21. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, Larson R, Zhang J, Protopopov A, Chin L, Pandolfi PP, Silverman LB, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009; 114(3):647-650.
22. Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, LaFiura K, Haska CL, Cherian C, Devidas M, Linda SB, Taub JW and Matherly LH. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2009; 23(8):1417-1425.
23. Jotta PY, Ganazza MA, Silva A, Viana MB, da Silva MJ, Zambaldi LJ, Barata JT, Brandalise SR and Yunes JA. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2010; 24(1):239-242.
24. Georgescu MM, Kirsch KH, Akagi T, Shishido T and Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(18):10182-10187.
25. Jjingo D, Conley AB, Yi SV, Lunyak VV and Jordan IK. On the presence and role of human gene-body DNA methylation. Oncotarget. 2012; 3(4):462-474.
26. Khan H, Vale C, Bhagat T and Verma A. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Seminars in hematology. 2013; 50(1):16-37.
27. Montiel-Duarte C, Cordeu L, Agirre X, Roman-Gomez J, Jimenez-Velasco A, Jose-Eneriz ES, Garate L, Andreu EJ, Calasanz MJ, Heiniger A, Torres A and Prosper F. Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leukemia research. 2008; 32(5):709-716.
28. Liu YL, Castleberry RP and Emanuel PD. PTEN deficiency is a common defect in juvenile myelomonocytic leukemia. Leukemia research. 2009; 33(5):671-677.
29. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, Ambesi-Impiombato A, Califano A, Migliazza A, Bhagat G and Dalla-Favera R. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer cell. 2010; 17(1):28-40.
30. Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons A, Balague O, Gel B, Abrisqueta P, Lopez-Guillermo A, Artells R, Montserrat E and Monzo M. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood. 2008; 111(5):2825-2832.
31. Yamanaka Y, Tagawa H, Takahashi N, Watanabe A, Guo YM, Iwamoto K, Yamashita J, Saitoh H, Kameoka Y, Shimizu N, Ichinohasama R and Sawada K. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood. 2009; 114(15):3265-3275.
32. Brodersen P, Sakvarelidze-Achard L, Bruun-Rasmussen M, Dunoyer P, Yamamoto YY, Sieburth L and Voinnet O. Widespread translational inhibition by plant miRNAs and siRNAs. Science. 2008; 320(5880):1185-1190.
33. He L and Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nature reviews Genetics. 2004; 5(7):522-531.
34. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Burge CB. Prediction of mammalian microRNA targets. Cell. 2003; 115(7):787-798.
35. Lewis BP, Burge CB and Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20.
36. Esquela-Kerscher A and Slack FJ. Oncomirs-microRNAs with a role in cancer. Nature reviews Cancer. 2006; 6(4):259-269.
37. Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gulla A, Rossi M, Neri A, Giordano A, Munshi NC, Anderson KC, Tagliaferri P and Tassone P. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(8):2096-2106.
38. Zhang J-G, Wang J-J, Zhao F, Liu Q, Jiang K and Yang G-H. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clinica Chimica Acta. 2010; 411(11-12):846-852.
39. Bai H, Xu R, Cao Z, Wei D and Wang C. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS letters. 2011; 585(2):402-408.
40. Folini M, Gandellini P, Longoni N, Profumo V, Callari M, Pennati M, Colecchia M, Supino R, Veneroni S, Salvioni R, Valdagni R, Daidone MG and Zaffaroni N. miR-21: an oncomir on strike in prostate cancer. Molecular cancer. 2010; 9.
41. Tian L, Fang YX, Xue JL and Chen JZ. Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro. PloS one. 2013; 8(9):e75885.
42. Havelange V, Stauffer N, Heaphy CCE, Volinia S, Andreeff M, Marcucci G, Croce CM and Garzon R. Functional Implications of MicroRNAs in Acute Myeloid Leukemia by Integrating MicroRNA and Messenger RNA Expression Profiling. Cancer. 2011; 117(20):4696-4706.
43. Liu B, Wu X, Wang C, Liu Y, Zhou Q and Xu K. MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochimica et biophysica acta. 2012; 1822(11):1692-1704.
44. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ and International Workshop on Chronic Lymphocytic L. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-5456.